Intercept Pharmaceuticals Inc (NASDAQ:ICPT) was downgraded by Citigroup Inc. from a “buy” rating to a “neutral” rating in a research report issued on Friday. They currently have a $92.00 target price on the biopharmaceutical company’s stock, down from their prior target price of $150.00. Citigroup Inc.’s price objective indicates a potential upside of 49.37% from the stock’s previous close.

Several other research firms also recently issued reports on ICPT. Laidlaw reissued a “hold” rating and issued a $119.00 target price (up from $115.00) on shares of Intercept Pharmaceuticals in a research report on Tuesday, August 1st. Cowen and Company reissued an “outperform” rating and issued a $232.00 target price on shares of Intercept Pharmaceuticals in a research report on Thursday, September 14th. BMO Capital Markets upped their target price on Intercept Pharmaceuticals from $218.00 to $221.00 and gave the company an “outperform” rating in a research report on Tuesday, August 1st. BidaskClub raised Intercept Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, August 24th. Finally, Cantor Fitzgerald reissued an “underweight” rating and issued a $69.00 target price on shares of Intercept Pharmaceuticals in a research report on Wednesday, September 13th. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $174.93.

Shares of Intercept Pharmaceuticals (ICPT) opened at 61.59 on Friday. The company has a 50 day moving average price of $106.75 and a 200 day moving average price of $115.74. Intercept Pharmaceuticals has a one year low of $60.97 and a one year high of $172.95. The company’s market cap is $1.55 billion.

Intercept Pharmaceuticals (NASDAQ:ICPT) last released its earnings results on Monday, July 31st. The biopharmaceutical company reported ($3.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.62) by $0.16. Intercept Pharmaceuticals had a negative return on equity of 169.39% and a negative net margin of 280.26%. The firm had revenue of $30.89 million for the quarter, compared to the consensus estimate of $27.50 million. During the same period in the prior year, the firm earned ($3.14) EPS. The firm’s revenue was up 459.6% on a year-over-year basis. Equities analysts predict that Intercept Pharmaceuticals will post ($13.91) EPS for the current year.

WARNING: “Intercept Pharmaceuticals Inc (ICPT) Stock Rating Lowered by Citigroup Inc.” was first published by Daily Political and is the property of of Daily Political. If you are viewing this news story on another site, it was stolen and reposted in violation of international trademark & copyright law. The original version of this news story can be read at https://www.dailypolitical.com/2017/09/24/intercept-pharmaceuticals-inc-icpt-stock-rating-lowered-by-citigroup-inc.html.

In other news, Director Daniel G. Welch sold 217 shares of the stock in a transaction dated Thursday, July 20th. The shares were sold at an average price of $126.76, for a total transaction of $27,506.92. Following the sale, the director now directly owns 3,710 shares of the company’s stock, valued at approximately $470,279.60. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CMO David Shapiro sold 1,250 shares of the stock in a transaction dated Friday, September 1st. The stock was sold at an average price of $117.43, for a total transaction of $146,787.50. Following the sale, the chief marketing officer now directly owns 45,812 shares in the company, valued at $5,379,703.16. The disclosure for this sale can be found here. Over the last three months, insiders have sold 48,013 shares of company stock worth $6,198,747. Corporate insiders own 9.20% of the company’s stock.

A number of institutional investors have recently modified their holdings of ICPT. WFG Advisors LP lifted its stake in Intercept Pharmaceuticals by 16.4% in the 2nd quarter. WFG Advisors LP now owns 888 shares of the biopharmaceutical company’s stock valued at $108,000 after buying an additional 125 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Intercept Pharmaceuticals by 14.4% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,047 shares of the biopharmaceutical company’s stock valued at $118,000 after buying an additional 132 shares in the last quarter. US Bancorp DE purchased a new position in Intercept Pharmaceuticals in the 1st quarter valued at about $130,000. IFP Advisors Inc lifted its stake in Intercept Pharmaceuticals by 128.1% in the 2nd quarter. IFP Advisors Inc now owns 1,300 shares of the biopharmaceutical company’s stock valued at $157,000 after buying an additional 730 shares in the last quarter. Finally, Quantbot Technologies LP purchased a new position in Intercept Pharmaceuticals in the 1st quarter valued at about $170,000. 82.19% of the stock is currently owned by hedge funds and other institutional investors.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.